BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Allen C, Mcdonald C, Giannini C, Peng KW, Rosales G, Russell SJ, Galanis E. Adenoviral vectors expressing fusogenic membrane glycoproteins activated via matrix metalloproteinase cleavable linkers have significant antitumor potential in the gene therapy of gliomas. J Gene Med 2004;6:1216-27. [DOI: 10.1002/jgm.616] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
Number Citing Articles
1 Lin E, Salon C, Brambilla E, Lavillette D, Szecsi J, Cosset F, Coll J. Fusogenic membrane glycoproteins induce syncytia formation and death in vitro and in vivo: a potential therapy agent for lung cancer. Cancer Gene Ther 2010;17:256-65. [DOI: 10.1038/cgt.2009.74] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
2 Lohberger B, Rinner B, Stuendl N, Kaltenegger H, Steinecker-Frohnwieser B, Bernhart E, Bonyadi Rad E, Weinberg AM, Leithner A, Bauer R, Kretschmer N. Sesquiterpene lactones downregulate G2/M cell cycle regulator proteins and affect the invasive potential of human soft tissue sarcoma cells. PLoS One 2013;8:e66300. [PMID: 23799090 DOI: 10.1371/journal.pone.0066300] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
3 Del Papa J, Parks RJ. Adenoviral Vectors Armed with Cell Fusion-Inducing Proteins as Anti-Cancer Agents. Viruses 2017;9:E13. [PMID: 28106842 DOI: 10.3390/v9010013] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
4 Cutter JL, Kurozumi K, Chiocca EA, Kaur B. Gene therapeutics: the future of brain tumor therapy? Expert Rev Anticancer Ther 2006;6:1053-64. [PMID: 16831077 DOI: 10.1586/14737140.6.7.1053] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
5 Isaacson KJ, Martin Jensen M, Subrahmanyam NB, Ghandehari H. Matrix-metalloproteinases as targets for controlled delivery in cancer: An analysis of upregulation and expression. J Control Release 2017;259:62-75. [PMID: 28153760 DOI: 10.1016/j.jconrel.2017.01.034] [Cited by in Crossref: 49] [Cited by in F6Publishing: 46] [Article Influence: 9.8] [Reference Citation Analysis]
6 Zheng D, Dan Y, Yang SH, Liu GH, Shao ZW, Yang C, Xiao BJ, Liu X, Wu S, Zhang T, Chu PK. Controlled chondrogenesis from adipose-derived stem cells by recombinant transforming growth factor-β3 fusion protein in peptide scaffolds. Acta Biomater 2015;11:191-203. [PMID: 25257317 DOI: 10.1016/j.actbio.2014.09.030] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
7 Krabbe T, Altomonte J. Fusogenic Viruses in Oncolytic Immunotherapy. Cancers (Basel) 2018;10:E216. [PMID: 29949934 DOI: 10.3390/cancers10070216] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
8 Guedan S, Gros A, Cascallo M, Vile R, Mercade E, Alemany R. Syncytia formation affects the yield and cytotoxicity of an adenovirus expressing a fusogenic glycoprotein at a late stage of replication. Gene Ther 2008;15:1240-5. [PMID: 18509378 DOI: 10.1038/gt.2008.94] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
9 Chen HH, Cawood R, El-Sherbini Y, Purdie L, Bazan-Peregrino M, Seymour LW, Carlisle RC. Active adenoviral vascular penetration by targeted formation of heterocellular endothelial-epithelial syncytia. Mol Ther 2011;19:67-75. [PMID: 20877345 DOI: 10.1038/mt.2010.209] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
10 Matveeva OV, Guo ZS, Shabalina SA, Chumakov PM. Oncolysis by paramyxoviruses: multiple mechanisms contribute to therapeutic efficiency. Mol Ther Oncolytics 2015;2:15011. [PMID: 26640816 DOI: 10.1038/mto.2015.11] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 4.4] [Reference Citation Analysis]
11 Kinoh H, Inoue M, Komaru A, Ueda Y, Hasegawa M, Yonemitsu Y. Generation of optimized and urokinase-targeted oncolytic Sendai virus vectors applicable for various human malignancies. Gene Ther. 2009;16:392-403. [PMID: 19037241 DOI: 10.1038/gt.2008.167] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
12 Goradel NH, Negahdari B, Ghorghanlu S, Jahangiri S, Arashkia A. Strategies for enhancing intratumoral spread of oncolytic adenoviruses. Pharmacol Ther 2020;213:107586. [PMID: 32479843 DOI: 10.1016/j.pharmthera.2020.107586] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
13 Del Papa J, Clarkin RG, Parks RJ. Use of cell fusion proteins to enhance adenoviral vector efficacy as an anti-cancer therapeutic. Cancer Gene Ther 2021;28:745-56. [DOI: 10.1038/s41417-020-0192-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Vartak DG, Gemeinhart RA. Matrix metalloproteases: underutilized targets for drug delivery. J Drug Target 2007;15:1-20. [PMID: 17365270 DOI: 10.1080/10611860600968967] [Cited by in Crossref: 95] [Cited by in F6Publishing: 88] [Article Influence: 6.3] [Reference Citation Analysis]